Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings per share (EPS) is N/A as of the fiscal period ended Tuesday, March 31, 2026.
Reported quarterly EPS; no daily interpolation. Q4 FY2026 (2026-03-31): 0.14.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 14 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T21:03:36.966Z. Historical observations retain their original dates. Historical series through 2025-07-31.
EARNINGS PER SHARE (EPS)
N/A
EARNINGS PER SHARE (EPS) AVG TTM
-8.66
EARNINGS PER SHARE (EPS) AVG 3Y
-10.78
EARNINGS PER SHARE (EPS) AVG 5Y
-46.09
EARNINGS PER SHARE (EPS) AVG 10Y
-58.83
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
China SXT Pharmaceuticals, Inc.
Market Cap
$667469.00
Earnings Per Share (EPS)
N/A
TTM Avg
-8.66
3Y Avg
-10.78
5Y Avg
-46.09
Market Cap
$716854.00
Earnings Per Share (EPS)
-5669.00
TTM Avg
-313854.00
3Y Avg
-213259.50
5Y Avg
-170757.60
Market Cap
$545796.00
Earnings Per Share (EPS)
-54.17
TTM Avg
-34.20
3Y Avg
-18.78
5Y Avg
-13.04
Market Cap
$518606.00
Earnings Per Share (EPS)
-6.04
TTM Avg
-3.52
3Y Avg
-12.52
5Y Avg
-15.85
Market Cap
$824550.00
Earnings Per Share (EPS)
-29.09
TTM Avg
-56.46
3Y Avg
-589.82
5Y Avg
-783.52
Market Cap
$835994.00
Earnings Per Share (EPS)
-233.09
TTM Avg
20691.39
3Y Avg
-239348.05
5Y Avg
-408377.87
Market Cap
$838843.00
Earnings Per Share (EPS)
-11.80
TTM Avg
-236.00
3Y Avg
-263.84
5Y Avg
-205.13
Market Cap
$481786.00
Earnings Per Share (EPS)
-2.74
TTM Avg
-4.14
3Y Avg
-35.99
5Y Avg
-26.33
Market Cap
$868077.00
Earnings Per Share (EPS)
-1.86
TTM Avg
-3.74
3Y Avg
-18.16
5Y Avg
-24.28
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| China SXT Pharmaceuticals, Inc. (SXTC) | $667469.00 | N/A | -8.66 | -10.78 | -46.09 |
| CDT Equity Inc. (CDT)vs › | $716854.00 | -5669.00 | -313854.00 | -213259.50 | -170757.60 |
| HCW Biologics Inc. (HCWB)vs › | $545796.00 | -54.17 | -34.20 | -18.78 | -13.04 |
| VivoSim Labs, Inc. (VIVS)vs › | $518606.00 | -6.04 | -3.52 | -12.52 | -15.85 |
| Decoy Therapeutics Inc. (DCOY)vs › | $824550.00 | -29.09 | -56.46 | -589.82 | -783.52 |
| Ridgetech, Inc. (RDGT)vs › | $835994.00 | -233.09 | 20691.39 | -239348.05 | -408377.87 |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $838843.00 | -11.80 | -236.00 | -263.84 | -205.13 |
| XORTX Therapeutics Inc. (XRTX)vs › | $481786.00 | -2.74 | -4.14 | -35.99 | -26.33 |
| Bone Biologics Corporation (BBLG)vs › | $868077.00 | -1.86 | -3.74 | -18.16 | -24.28 |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | -180.45 | -617.40 | -559.80 | -483.70 |
Trailing EPS (TTM)
N/A
Forward EPS (Est.)
N/A
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2026-03-31 | -9.13 |
| 2025-03-31 | -8.18 |
| 2024-03-31 | -3.57 |
| 2023-03-31 | -22.23 |
| 2022-03-31 | -137.92 |
| 2021-03-31 | -95.48 |
| 2020-03-31 | -832.08 |
| 2019-03-31 | 149.67 |
| 2018-03-31 | 100.01 |
| 2017-03-31 | 99.80 |
| 2016-03-31 | 112.00 |
